AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18589423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg daily for 15 days
Number of subjects: 22
Study 18589423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15827459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk odor
Number of subjects: 44
Study 15827459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanilla smell
Number of subjects: 44
Study 15827459 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar odor
Number of subjects: 44
Study 15827459 — intervention group
Group type: COMPARATOR
Intervention: No odor (Control group)
Number of subjects: 44
Study 11830307 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated regimen (AF): 66Gy given in 33 fractions over 38 days.
Number of subjects: 395
Study 11830307 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (CF): 66Gy given in 33 fractions over 45 days.
Number of subjects: 395
Study 10512078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 105
Study 10512078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 105
Study 10512078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (Pimozide and Lithium)
Number of subjects: 105
Study 10512078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 7740123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal conditioning with intermixed pre-training and compound training trials; specific dosage and duration not mentioned.
Number of subjects: 0
Study 7740123 — intervention group
Group type: COMPARATOR
Intervention: Overshadowing control group; specific dosage and duration not mentioned.
Number of subjects: 0
Study 2167327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental tape
Number of subjects: 20
Study 2167327 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxed dental floss
Number of subjects: 20
Study 2167327 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfloss
Number of subjects: 20
Study 2167327 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of dental floss
Number of subjects: 20
Study 6290754 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and vincristine (ACO)
Number of subjects: 103
Study 6290754 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide maintenance therapy
Number of subjects: 103
Study 6290754 — intervention group
Group type: COMPARATOR
Intervention: No further maintenance therapy
Number of subjects: 103
Study 6290754 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 103
Study 6290754 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation towards primary disease sites
Number of subjects: 103
Study 6290754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen (ACO)
Number of subjects: 103
Study 30897134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and pulmonary rehabilitation
Number of subjects: 95
Study 30897134 — intervention group
Group type: COMPARATOR
Intervention: Usual care cohort
Number of subjects: 95
Study 30897134 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity or sleep
Number of subjects: 95
Study 30897134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour or light physical activity
Number of subjects: 95
Study 28337854 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk fibroin film
Number of subjects: 71
Study 28337854 — intervention group
Group type: COMPARATOR
Intervention: Commercial dressing
Number of subjects: 71
Study 26257796 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 40
Study 26257796 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (Control)
Number of subjects: 40
Study 23279709 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist cool air device (MCAD) exposure
Number of subjects: 20
Study 23279709 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MCAD)
Number of subjects: 20
Study 21554520 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 36
Study 21554520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18813028 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS+LGG powder containing 10(10) CFU (group B)
Number of subjects: 559
Study 18813028 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS+LGG powder containing 10(12) CFU (group C)
Number of subjects: 559
Study 18813028 — intervention group
Group type: COMPARATOR
Intervention: ORS (group A/control)
Number of subjects: 559
Study 17542944 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1.5 mg)
Number of subjects: 8
Study 17542944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15363007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (800 micro g budesonide) for 12 weeks
Number of subjects: 38
Study 15363007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11822764 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide
Number of subjects: 690
Study 11822764 — intervention group
Group type: COMPARATOR
Intervention: no etoposide
Number of subjects: 690
Study 11822764 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose therapy
Number of subjects: 690
Study 9516059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg) over 4 weeks
Number of subjects: 9
Study 9516059 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study 8071053 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (370 mg I/mL)
Number of subjects: 161
Study 8071053 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (370 mg I/mL)
Number of subjects: 161
Study 8071053 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (350 mg I/mL)
Number of subjects: 161
Study 3127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline at low plasma drug levels
Number of subjects: 74
Study 3127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline at medium plasma drug levels
Number of subjects: 74
Study 3127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline at high plasma drug levels
Number of subjects: 74
Study 3127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment in patients aged 25 to 65 years
Number of subjects: 74
Study 3127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment in patients aged 65 to 80 years
Number of subjects: 74
Study 29610026 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal crosslinking (CXL) using higher fluence (7.2 J/cm2) and treatment time (4 minutes)
Number of subjects: 20
Study 29610026 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal crosslinking (CXL)
Number of subjects: 20
Study 27716157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (6.7 ml)
Number of subjects: 99
Study 27716157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (10 ml)
Number of subjects: 99
Study 27716157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (20 ml)
Number of subjects: 99
Study 27716157 — intervention group
Group type: COMPARATOR
Intervention: All groups (0.75%, 0.5%, 0.25%)
Number of subjects: 99
Study 24724093 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid PTSD/mTBI
Number of subjects: 0
Study 24724093 — intervention group
Group type: COMPARATOR
Intervention: Control group (OEF/OIF Veterans with no history of mTBI and/or PTSD)
Number of subjects: 0
Study 24071759 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management program
Number of subjects: 65
Study 24071759 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 65
Study 20575271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccine
Number of subjects: 0
Study 20575271 — intervention group
Group type: COMPARATOR
Intervention: Hi culture positive
Number of subjects: 0
Study 17568397 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 8
Study 17568397 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/day
Number of subjects: 8
Study 17568397 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0, 12, 25, and 50 mg)
Number of subjects: 8
Study 17646493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 microg/kg
Number of subjects: 18
Study 17646493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1.5 microg/kg
Number of subjects: 18
Study 17646493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14692723 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava special extract WS 1490 (150 mg/d, 3 x 1 capsule of 50 mg/d)
Number of subjects: 141
Study 14692723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 14692723 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava special extract WS 1490
Number of subjects: 141
Study 10981439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support (PS) ventilation
Number of subjects: 18
Study 10981439 — intervention group
Group type: COMPARATOR
Intervention: Amplified Spontaneous Pattern (ASP) ventilation
Number of subjects: 18
Study 9062416 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visit
Number of subjects: 212
Study 9062416 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up preference
Number of subjects: 212
Study 9062416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 212
Study 8103473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 54
Study 8103473 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal insemination (IPI)
Number of subjects: 54
Study 3769570 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism
Number of subjects: 3
Study 31571341 — intervention group
Group type: EXPERIMENTAL
Intervention: Full exposure to crowdsourced images and videos intervention
Number of subjects: 470
Study 31571341 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial exposure to crowdsourced images and videos intervention
Number of subjects: 470
Study 31571341 — intervention group
Group type: COMPARATOR
Intervention: No exposure to intervention
Number of subjects: 470
Study 31571341 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having a recent doctor's visit
Number of subjects: 470
Study 29275505 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RP‐NF (mind-body program)
Number of subjects: 63
Study 29275505 — intervention group
Group type: COMPARATOR
Intervention: Control (attention placebo)
Number of subjects: 63
Study 26756977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil-Ambrisentan (S+A)
Number of subjects: 0
Study 26756977 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil-Bosentan (S+B)
Number of subjects: 0
Study 24980440 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Treatment (IT)
Number of subjects: 120
Study 24980440 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Acupuncture (TA)
Number of subjects: 120
Study 24980440 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 120
Study 21998264 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 12)
Number of subjects: 25
Study 21998264 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (n = 13)
Number of subjects: 25
Study 20553591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior discectomy only
Number of subjects: 0
Study 20553591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior discectomy with interbody fusion
Number of subjects: 0
Study 20553591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior discectomy with disc prosthesis
Number of subjects: 0
Study 20553591 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18279823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring by experienced chairs
Number of subjects: 27
Study 18279823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mentoring)
Number of subjects: 27
Study 15735200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 18
Study 15735200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12927999 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer cytotoxic agents (gemcitabine, PEG-liposomal doxorubicin, topotecan) in combination with platinum-based therapy
Number of subjects: 3400
Study 12927999 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum/taxane therapy (carboplatin and paclitaxel)
Number of subjects: 3400
Study 11261633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0
Study 11261633 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9251377 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 62
Study 9251377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1622957 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 5% eutectic mixture of lignocaine and prilocaine (EMLA) (n = 15)
Number of subjects: 45
Study 1622957 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (similar emulsion containing no local anaesthetic) (n = 15)
Number of subjects: 45
Study 1622957 — intervention group
Group type: COMPARATOR
Intervention: Control group (infiltration anaesthesia with lignocaine if requested) (n = 15)
Number of subjects: 45
Study 6381775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam and ampicillin sodium therapy
Number of subjects: 63
Study 6381775 — intervention group
Group type: COMPARATOR
Intervention: Amikacin sulfate and ampicillin therapy
Number of subjects: 63
Study 30458757 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay of Event (DoE) of 18 months
Number of subjects: 1041
Study 30458757 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay of Event (DoE) of 6 months
Number of subjects: 1041
Study 30458757 — intervention group
Group type: COMPARATOR
Intervention: Delay of Event (DoE) of 1 month
Number of subjects: 1041
Study 26686567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide (10-60 mg)
Number of subjects: 72
Study 26686567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24794720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg nitroglycerin gel (1 mL) applied vaginally 30 min prior to IUD placement
Number of subjects: 24
Study 24794720 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo gel applied vaginally 30 min prior to IUD placement
Number of subjects: 24
Study 22506466 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (MCL rupture)
Number of subjects: 127
Study 22506466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MCL rupture)
Number of subjects: 127
Study 20350942 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc-ritonavir (30 and 100 mg)
Number of subjects: 230
Study 20350942 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc-ritonavir (150 and 100 mg)
Number of subjects: 230
Study 20350942 — intervention group
Group type: EXPERIMENTAL
Intervention: ritonavir (100 mg)
Number of subjects: 230
Study 20350942 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc (200, 250, or 300 mg)
Number of subjects: 230
Study 20350942 — intervention group
Group type: EXPERIMENTAL
Intervention: vicriviroc (150, 200, or 250 mg)
Number of subjects: 230
Study 20350942 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 230
Study 18581699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 24 weeks
Number of subjects: 48
Study 18581699 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 16227990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy consisting of a single early post-transplant infusion of in vivo vaccine-primed and ex vivo costimulated autologous T cells followed by post-transplant booster immunizations
Number of subjects: 0
Study 16227990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early T-cell infusions
Number of subjects: 0
Study 16227990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine therapy and adoptive T-cell transfer
Number of subjects: 0
Study 11927062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 gauss magnet
Number of subjects: 30
Study 11927062 — intervention group
Group type: COMPARATOR
Intervention: Placebo metal disk
Number of subjects: 30
Study 9456253 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir in combination with nucleoside analogue reverse transcriptase inhibitors
Number of subjects: 14
Study 7610506 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH analogues treatment
Number of subjects: 29
Study 2540581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine (up to 1050 mg/day)
Number of subjects: 25
Study 2540581 — intervention group
Group type: COMPARATOR
Intervention: MVP (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 25
Study 779590 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (400 mg daily, increased to 533 mg)
Number of subjects: 22
Study 779590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg daily, increased to 25 mg)
Number of subjects: 22
Study 29535447 — intervention group
Group type: EXPERIMENTAL
Intervention: Grand Theft Auto V (violent video game)
Number of subjects: 0
Study 29535447 — intervention group
Group type: EXPERIMENTAL
Intervention: The Sims 3 (non-violent video game)
Number of subjects: 0
Study 29535447 — intervention group
Group type: COMPARATOR
Intervention: No game (passive control group)
Number of subjects: 0
Study 28802804 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) delivered to the left DLPFC for a single 20-minute session
Number of subjects: 44
Study 28802804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44
Study 25777588 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based SHED-IT WLM Program
Number of subjects: 92
Study 25777588 — intervention group
Group type: COMPARATOR
Intervention: Self-help control group
Number of subjects: 92
Study 23295101 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced transesophageal echocardiography (TEE)
Number of subjects: 180
Study 23295101 — intervention group
Group type: COMPARATOR
Intervention: Native transesophageal echocardiography (TEE)
Number of subjects: 180
Study 23295101 — intervention group
Group type: COMPARATOR
Intervention: Control group (native TEE)
Number of subjects: 180
Study 23295101 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced TEE
Number of subjects: 180
Study 21671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) administered twice daily for 10 days
Number of subjects: 0
Study 21671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) administered twice daily for 10 days
Number of subjects: 0
Study 21671884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) administered alone for 10 days
Number of subjects: 0
Study 21671884 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg single dose)
Number of subjects: 0
Study 19920048 — intervention group
Group type: EXPERIMENTAL
Intervention: Binodenoson 1.5 microg/kg
Number of subjects: 87
Study 19920048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16954734 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide discontinued
Number of subjects: 18
Study 16954734 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide continued
Number of subjects: 18
Study 9918280 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 41
Study 9918280 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs
Number of subjects: 41
Study 9918280 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipment
Number of subjects: 41
Study 9918280 — intervention group
Group type: EXPERIMENTAL
Intervention: Other interventions
Number of subjects: 41
Study 8752811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 0
Study 8752811 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 1671361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.5 microgram/kg per minute)
Number of subjects: 8
Study 1671361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6859836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 or 200 mg daily for 5 days)
Number of subjects: 47
Study 6859836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.25 g daily for 5 days)
Number of subjects: 47
Study 31912226 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise (RE) at 50% of maximal voluntary contraction for 20 seconds
Number of subjects: 11
Study 31912226 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise (RE)
Number of subjects: 11
Study 31912226 — intervention group
Group type: COMPARATOR
Intervention: Valsalva manoeuvre (VM)
Number of subjects: 11
Study 30944112 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 294
Study 30944112 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI)
Number of subjects: 294
Study 30944112 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 294
Study 30944112 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 294
Study 30072404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 22379
Study 30072404 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones
Number of subjects: 22379
Study 26432693 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based depression care management for 2 years, including psychotherapy and medication management
Number of subjects: 1204
Study 26432693 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1204